Rxivist combines preprints from bioRxiv with data from Twitter to help you find the papers being discussed in your field. Currently indexing 70,762 bioRxiv papers from 308,879 authors.
New insights on the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation
By
Chiara Fabbri,
Katherine E. Tansey,
Roy H. Perlis,
Joanna Hauser,
Neven Henigsberg,
Wolfgang Maier,
Ole Mors,
Anna Placentino,
Marcella Rietschel,
Daniel Souery,
Gerome Breen,
Charles Curtis,
Lee Sang-Hyuk,
Stephen Newhouse,
Hamel Patel,
Michel Guipponi,
Nader Perroud,
Guido Bondolfi,
Micheal O’Donovan,
Glyn Lewis,
Joanna M. Biernacka,
Richard M. Weinshilboum,
Anne Farmer,
Katherine J. Aitchison,
Ian Craig,
Peter McGuffin,
Rudolf Uher,
Cathryn M. Lewis
Posted 20 Feb 2017
bioRxiv DOI: 10.1101/109827
(published DOI: 10.1038/tpj.2017.44)
Genome-wide association studies have generally failed to identify polymorphisms associated with antidepressant response. Possible reasons include limited coverage of genetic variants that this study tried to address by exome genotyping and dense imputation. A meta-analysis of Genome-Based Therapeutic Drugs for Depression (GENDEP) and Sequenced Treatment Alternatives to Relieve Depression (STAR*D) studies was performed at SNP, gene and pathway level. Coverage of genetic variants was increased compared to previous studies by adding exome genotypes to previously available genome-wide data and using the Haplotype Reference Consortium panel for imputation. Standard quality control was applied. Phenotypes were symptom improvement and remission after 12 weeks of antidepressant treatment. NEWMEDS consortium samples and Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) served for replication. 7,062,950 SNPs were analysed in GENDEP (n=738) and STAR*D (n=1409). rs116692768 (p=1.80e-08, ITGA9 (integrin alpha 9)) and rs76191705 (p=2.59e-08, NRXN3 (neurexin 3)) were significantly associated with symptom improvement during citalopram/escitalopram treatment. At gene level, no consistent effect was found. At pathway level, the Gene Ontology terms GO:0005694 (chromosome) and GO:0044427 (chromosomal part) were associated with improvement (corrected p=0.007 and 0.045, respectively). The association between rs116692768 and symptom improvement was replicated in PGRN-AMPS (p=0.047), while rs76191705 was not. The two SNPs did not replicate in NEWMEDS. ITGA9 codes for a membrane receptor for neurotrophins and NRXN3 is a transmembrane neuronal adhesion receptor involved in synaptic differentiation. Despite their meaningful biological rationale for being involved in antidepressant effect, no convincing replication was achieved. Further studies may help in clarifying their role.
Download data
- Downloaded 498 times
- Download rankings, all-time:
- Site-wide: 22,828 out of 70,744
- In genomics: 2,538 out of 4,722
- Year to date:
- Site-wide: 64,139 out of 70,744
- Since beginning of last month:
- Site-wide: 60,717 out of 70,744
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!